Shimla Online

Graft Versus Host Disease (GvHD) Market to Witness Growth by 2032, Estimates DelveInsight | AstraZeneca, Biogen, Amgen, Pfizer, AltruBio, CSL Behring, Incyte Corporation, Takeda, OncoImmune, Merck

 Breaking News
  • No posts were found

Graft Versus Host Disease (GvHD) Market to Witness Growth by 2032, Estimates DelveInsight | AstraZeneca, Biogen, Amgen, Pfizer, AltruBio, CSL Behring, Incyte Corporation, Takeda, OncoImmune, Merck

April 20
00:36 2023
Graft Versus Host Disease (GvHD) Market to Witness Growth by 2032, Estimates DelveInsight | AstraZeneca, Biogen, Amgen, Pfizer, AltruBio, CSL Behring, Incyte Corporation, Takeda, OncoImmune, Merck
Graft Versus Host Disease (GvHD) Market

(Las Vegas, Nevada, USA) DelveInsight’s “Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology as well as the Graft Versus Host Disease (GvHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Graft Versus Host Disease (GvHD) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Graft Versus Host Disease (GvHD) market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Graft Versus Host Disease (GvHD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Graft Versus Host Disease (GvHD) market.

 

Request for a Free Sample Report @ Graft Versus Host Disease Market Forecast

 

Some facts of the Graft Versus Host Disease (GvHD) Market Report are:

  • According to DelveInsight, Graft Versus Host Disease (GvHD) market size is expected to reach USD XX Million by 2032.
  • Leading Graft Versus Host Disease (GvHD) companies working in the market are Medac, MaaT Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceutical, Kadmon Corporation, AstraZeneca, Biogen, Amgen, Pfizer, AltruBio, CSL Behring, Incyte Corporation, Takeda, OncoImmune, Merck (MSD), Regimmune Corporation, Jazz Pharmaceuticals, Millennium Pharmaceuticals, Takeda Oncology, Roche, Genentech, Bristol-Myers Squibb, Xenikos, Synthetic Biologics, Equillium/Biocon, CTI BioPharma, Novartis, GlaxoSmithKline and others.
  • Key Graft Versus Host Disease (GvHD) Therapies expected to launch in the market are Jakafi (Ruxolitinib), Temcell (Ryoncil; Remestemcel-L; Prochymal), Obnitix (MC0518), MaaT013, Leukotac (Inolimomab), KD025 (Belumosudil), CSL 964 Alpha-1 antitrypsin, Itacitinib, and many others.
  • In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.

 

Graft Versus Host Disease (GvHD) Overview

 

GvHD is an immune condition that occurs when immune cells (T-cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem cell transplantation).The two main types of GvHD are acute GvHD and chronic GvHD. Other than this, GvHD is classified into other types, namely: classic acute GvHD, persistent, recurrent, late-onset acute GvHD, classic chronic GvHD, and overlap syndrome and de novo chronic GvHD. Patients who get acute GvHD have a 50% chance of developing chronic GvHD. Acute GvHD (aGvHD) might occur once the donor’s cells have engrafted in the transplant recipient and have been observed to affect skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant.

 

Learn more about Graft Versus Host Disease (GvHD) treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Graft Versus Host Disease (GvHD) Market 

The Graft Versus Host Disease (GvHD) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Graft Versus Host Disease (GvHD) market trends by analyzing the impact of current Graft Versus Host Disease (GvHD) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Graft Versus Host Disease (GvHD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Graft Versus Host Disease (GvHD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, the Graft Versus Host Disease (GvHD) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Graft Versus Host Disease (GvHD) Epidemiology

The Graft Versus Host Disease (GvHD) epidemiology section provides insights into the historical and current Graft Versus Host Disease (GvHD) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Graft Versus Host Disease (GvHD) market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Graft Versus Host Disease (GvHD) Epidemiology @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Graft Versus Host Disease (GvHD) Drugs Uptake

This section focuses on the uptake rate of the potential Graft Versus Host Disease (GvHD) drugs recently launched in the Graft Versus Host Disease (GvHD) market or expected to be launched in 2019-2032. The analysis covers the Graft Versus Host Disease (GvHD) market uptake by drugs, patient uptake by therapies, and sales of each drug.

Graft Versus Host Disease (GvHD) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Graft Versus Host Disease (GvHD) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Graft Versus Host Disease (GvHD) Pipeline Development Activities

The Graft Versus Host Disease (GvHD) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Graft Versus Host Disease (GvHD) key players involved in developing targeted therapeutics.

1. Obnitix (MC0518): Medac

2. MaaT013: MaaT Pharma

3. Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)

4. SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical

5. KD025 (Belumosudil): Kadmon Corporation

6. Calquence (Acalabrutinib): AstraZeneca

7. Tysabri (Natalizumab): Biogen

8. Efavaleukin Alfa (AMG 592): Amgen

9. Daurismo (Glasdegib): Pfizer

10. AbGn-168H (Neihulizumab): AltruBio

11. CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring

12. Itacitinib: Incyte Corporation

13. Entyvio (Vedolizumab; MLN0002): Takeda

14. MK-7110 (CD24Fc): OncoImmune/Merck (MSD)

15. RGI-2001: Regimmune Corporation

16. Defitelio (Defibrotide): Jazz Pharmaceuticals

17. Ninlaro (MLN 9708, MLN2238, Ixazomib): Millennium Pharmaceuticals/Takeda Oncology

18. Gazyva (Obinutuzumab): Roche-Genentech

19. Orencia (Abatacept): Bristol-Myers Squibb

20. T-Guard: Xenikos

21. SYN-004 (ribaxamase): Synthetic Biologics

22. EQ001 (Itolizumab; Bmab600): Equillium/Biocon

23. Pacritinib (Epjevy; ONX-0803): CTI BioPharma

24. Farydak (LBH-589, Panobinostat): Novartis

25. Benlysta (Belimumab): GlaxoSmithKline

 

Request for a sample report to understand more about the Graft Versus Host Disease (GvHD) pipeline development activities @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Graft Versus Host Disease (GvHD) Therapeutics Assessment

Major key companies are working proactively in the Graft Versus Host Disease (GvHD) Therapeutics market to develop novel therapies which will drive the Graft Versus Host Disease (GvHD) treatment markets in the upcoming years are Medac, MaaT Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceutical, Kadmon Corporation, AstraZeneca, Biogen, Amgen, Pfizer, AltruBio, CSL Behring, Incyte Corporation, Takeda, OncoImmune, Merck (MSD), Regimmune Corporation, Jazz Pharmaceuticals, Millennium Pharmaceuticals, Takeda Oncology, Roche, Genentech, Bristol-Myers Squibb, Xenikos, Synthetic Biologics, Equillium/Biocon, CTI BioPharma, Novartis, GlaxoSmithKline and others.

 

Learn more about the emerging GVHD therapies & key companies @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Graft Versus Host Disease (GvHD) Report Key Insights

1. Graft Versus Host Disease (GvHD) Patient Population

2. Graft Versus Host Disease (GvHD) Market Size and Trends

3. Key Cross Competition in the Graft Versus Host Disease (GvHD) Market

4. Graft Versus Host Disease (GvHD) Market Dynamics (Key Drivers and Barriers)

5. Graft Versus Host Disease (GvHD) Market Opportunities

6. Graft Versus Host Disease (GvHD) Therapeutic Approaches

7. Graft Versus Host Disease (GvHD) Pipeline Analysis

8. Graft Versus Host Disease (GvHD) Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Graft Versus Host Disease (GvHD) Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Graft Versus Host Disease (GvHD) Competitive Intelligence Analysis

4. Graft Versus Host Disease (GvHD) Market Overview at a Glance

5. Graft Versus Host Disease (GvHD) Disease Background and Overview

6. Graft Versus Host Disease (GvHD) Patient Journey

7. Graft Versus Host Disease (GvHD) Epidemiology and Patient Population

8. Graft Versus Host Disease (GvHD) Treatment Algorithm, Current Treatment, and Medical Practices

9. Graft Versus Host Disease (GvHD) Unmet Needs

10. Key Endpoints of Graft Versus Host Disease (GvHD) Treatment

11. Graft Versus Host Disease (GvHD) Marketed Products

12. Graft Versus Host Disease (GvHD) Emerging Therapies

13. Graft Versus Host Disease (GvHD) Seven Major Market Analysis

14. Attribute Analysis

15. Graft Versus Host Disease (GvHD) Market Outlook (7 major markets)

16. Graft Versus Host Disease (GvHD) Access and Reimbursement Overview

17. KOL Views on the Graft Versus Host Disease (GvHD) Market

18. Graft Versus Host Disease (GvHD) Market Drivers

19. Graft Versus Host Disease (GvHD) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Related Articles